Amalgamated Bank’s Passage Bio PASG Stock Holding History

Amalgamated Bank’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-224	Closed	-$14K	–	3156
2022 Q1	$14K	Buy	+224	New	+$18.5K	﹤0.01%	2897

Other funds holding PASG

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Amalgamated Bank's PASG Position: Q2 2022 in Review

Amalgamated Bank sold out of Passage Bio (PASG) in Q2 2022, closing a stake of 224 shares — an estimated $14K sold.

Amalgamated Bank first reported a position in PASG in Q1 2022 and held it in 1 quarter. The position peaked at $14K in Q1 2022. 85 funds tracked by Wall St. Rank hold PASG as of Q2 2022.

Amalgamated Bank reported no remaining Passage Bio position as of Q2 2022 after selling out during the quarter.
Amalgamated Bank sold 224 Passage Bio shares in Q2 2022, an estimated $14K.
Amalgamated Bank first reported a position in Passage Bio in Q1 2022 and held it in 1 quarter.
Amalgamated Bank's Passage Bio position peaked at $14K in Q1 2022.
85 funds tracked by Wall St. Rank held Passage Bio as of Q2 2022.

Based on Amalgamated Bank's 13F filing for Q2 2022, filed 15 Aug 2022.